poisar

Stocks · News reference

McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization

Vandana Singh

McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MCK
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sara Appino

    AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

    ABBVBMYCELGRMCKCAH
  2. Sara Appino

    AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

    The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

    ABBVCRSPVRTXMCKCAH
  4. Brendan Coffey

    AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

    ABBVPFEMCKCAHCOR